Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria Aragón (12)

2024

  1. A Randomized Trial on Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke (HOPE)

    Cerebrovascular Diseases

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  3. Thrombosis with thrombocytopenia syndrome following adenovirus vector-based vaccines to prevent COVID-19: Epidemiology and clinical presentation in Spain

    Neurologia, Vol. 39, Núm. 9, pp. 721-732

2023

  1. ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 6, pp. 479-482

  2. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project

    Orphanet Journal of Rare Diseases, Vol. 18, Núm. 1

2022

  1. Relationship between time from symptom's onset to diagnosis and prognosis in patients with symptomatic colorectal cancer

    BMC cancer, Vol. 22, Núm. 1, pp. 910

2021

  1. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy

    Journal of Biological Chemistry, Vol. 297, Núm. 1

2020

  1. Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain

    European Journal of Neurology, Vol. 27, Núm. 12, pp. 2491-2498

  2. Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain

    International Journal of Stroke, Vol. 15, Núm. 7, pp. 755-762

  3. Oral Anticoagulation and Risk of Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Mechanical Thrombectomy: Data From the Nordictus Registry

    Frontiers in Neurology, Vol. 11

2019

  1. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734